Form 4: Cocrystal Pharma Director Granted Stock Options

Cocrystal Pharma Director Roger D. Kornberg received a grant of 24,615 non-qualified stock options with an exercise price of $1.10.

Summary

• Director Roger D. Kornberg was granted 24,615 non-qualified stock options by Cocrystal Pharma, Inc. (COCP).
• The options have an exercise price of $1.10 per share.
• The transaction date for this grant was January 9, 2026.
• The options were granted under the Issuer's 2025 Equity Incentive Plan.
• One-half of the options will vest and become exercisable on January 9, 2027.
• The remaining half will vest in eight equal quarterly installments commencing on March 31, 2027.
• Vesting is subject to Mr. Kornberg continuing to serve as a director of the Issuer on each applicable vesting date.
• The options have an expiration date of January 9, 2036.
• The grant was approved by the Issuer's Compensation Committee of the Board of Directors and is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3.

Sentiment

Score: 6

Explanation: The grant of stock options is a positive incentive for the director, aligning their interests with shareholders, but it is a routine event and does not indicate significant new positive or negative developments for the company's operational or financial performance.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term performance.
• Equity compensation is a standard practice for attracting and retaining qualified board members in the biotechnology sector.

Negatives

• The future exercise of these options could lead to a minor dilution of existing shareholder equity, though this is a common aspect of equity compensation plans.

Risks

• The exercisability of the options is contingent upon the reporting person continuing to serve as a director of the Issuer on each applicable vesting date.
• The value of the options is dependent on the future market price of Cocrystal Pharma's common stock exceeding the $1.10 exercise price.

Future Outlook

The vesting schedule of the stock options, extending through quarterly installments commencing in March 2027, indicates a long-term incentive structure designed to retain the director and align their interests with the company's future performance.

Industry Context

The grant of stock options to a director is a common form of executive and board compensation in the biotechnology and pharmaceutical industries. It serves to attract and retain experienced professionals by offering a stake in the company's long-term success, which is particularly relevant for companies like Cocrystal Pharma focused on drug development.

Comparison to Industry Standards

• The use of a non-qualified stock option grant under an equity incentive plan is a standard compensation mechanism widely adopted across the biotechnology and pharmaceutical sectors.
• The vesting schedule, with an initial tranche followed by quarterly installments, is typical for incentivizing continued service and long-term commitment, comparable to practices at similar-stage biotech companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from aligned director incentives.
• Director (Roger D. Kornberg): Receives a significant equity incentive, aligning personal financial success with company performance and encouraging continued service.

Next Steps

• One-half of the options will vest on January 9, 2027.
• The remaining half of the options will begin vesting in eight equal quarterly installments starting March 31, 2027.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of stock options to an existing director as part of their compensation. While it aligns the director's interests with shareholders, it does not present new information that would fundamentally alter the company's valuation or investment thesis. Therefore, a 'hold' recommendation is appropriate as it does not provide a strong catalyst for a 'buy' or 'sell' decision.

Keywords

Cocrystal Pharma, COCP, Stock Options, Equity Grant, Director Compensation, Form 4, Insider Transaction, Non-Qualified Stock Options, Equity Incentive Plan